Press release
Ovarian Cancer Market Size is expected to witness a major change in the study period 2019-2032
The Ovarian Cancer market report provides current treatment practices, emerging drugs, Ovarian Cancer market share of the individual therapies, current and forecasted Ovarian Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Ovarian Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the Ovarian Cancer Market
•
According to DelveInsight's estimate, the total diagnosed incident cases of OC in the 7MM comprised 58,366 cases in 2022 and are projected to reach up to 46,086 cases by 2032. These cases are anticipated to decrease during the study period.
• According to DelveInsight, Ovarian Cancer market in 7MM is expected to witness a change in the study period 2019-2032.
• The leading Ovarian Cancer Market Companies include BioNumerik Pharmaceuticals Inc, Crown Bioscience, On Target Laboratories LLC, SynteractHCR, Johnson & Johnson Pharmaceutical Research & Development LLC, PharmaMar, AstraZeneca, Myriad Genetic Laboratories Inc, Merck Sharp & Dohme LLC, AGO Research GmbH, Hoffmann-La Roche, Iqvia Pty Ltd, Tesaro, Pfizer, and others.
• Promising Ovarian Cancer Pipeline Therapies include Active comparator: Niraparib, Chemotherapy + bevacizumab followed by bevacizumab, Niraparib, Olaparib, Chemotherapy, Atezolizumab, Bevacizumab, Single agent chemotherapy, OLAPARIB, Durvalumab, Dexamethasone, DOXIL, Trabectedin, OTL38, and others.
For more insights into the Ovarian Cancer Market Landscape, visit Ovarian Cancer Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Ovarian Cancer Overview
Cancer is a generic term in which abnormal cells in the body grow out of control. Cells in nearly any part of the body can become cancerous and spread. However, it is typically named for the part of the body where it starts, even if it spreads to other body parts later.
Recent Developmental Activities in the Ovarian Cancer Treatment Landscape
• The FDA cleared AVASTIN for platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel and pegylated liposomal doxorubicin, in November 2014. In June 2018, FDA approved AVASTIN for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for Stage III or IV disease after initial surgical resection.
• In December 2014, FDA approved LYNPARZA as the first monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated advanced OC who have been treated with three or more prior lines of chemotherapy.
• In August 2017, it was approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. In December 2018, it was approved for maintenance treatment of adult patients gBRCAm or sBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, as detected by an FDA-approved companion diagnostic test. Again in May 2020, FDA expanded the indication to include its combination with bevacizumab for first-line maintenance treatment of adult patients.
• In December 2016, the FDA approved RUBRACA as monotherapy for treating patients with deleterious BRCA mutation (germline and/or somatic) associated advanced OC who have been treated with two or more chemotherapies and selected for therapy based on an FDA-approved companion diagnostic. In April 2018, FDA approved RUBRACA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Ovarian Cancer Epidemiology Segmentation in the 7MM
• Total Ovarian Cancer Diagnosed Incident Cases
• Ovarian Cancer Type-specific Cases
• Ovarian Cancer Line-wise Treated Cases
• Ovarian Cancer Age-specific Cases
• Ovarian Cancer Stage-specific Cases
Download the report to understand which factors are driving Ovarian Cancer epidemiology trends, visit here for Ovarian Cancer Epidemiological Insights @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Ovarian Cancer Market Insights
In short, efficacious pharmacologic options for managing the most incident and disabling phases of OC are extremely limited. Treatments that work in both disorder phases are especially rare; therefore, new treatments are required. Nevertheless, recently some developmental initiatives have been taken toward the management of OC. As some interesting therapies are heading down the pipeline, the condition may evolve. This would encourage reimbursement of insurance, adoption by doctors, and compliance with patients. Currently, some companies have initiated clinical trials investigating new treatment options.
Ovarian Cancer Emerging Drugs
• RUBRACA (rucaparib): (Clovis Oncology)
• AVASTIN (bevacizumab): (Genentech/Roche)
• LYNPARZA (olaparib): (AstraZeneca/MSD)
• Batiraxcept (AVB-500): (Aravive Biologics)
• Stenoparib (2X-121): (Allarity Therapeutics)
• Relacorilant (CORT125134): (Corcept therapeutics)
Browse More Related Reports of the Ovarian Cancer Market Research Reports, click here for Ovarian Cancer Market Forecast @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Ovarian Cancer Market Report
• Coverage- 7MM
• Ovarian Cancer Companies- BioNumerik Pharmaceuticals Inc, Crown Bioscience, On Target Laboratories LLC, SynteractHCR, Johnson & Johnson Pharmaceutical Research & Development LLC, PharmaMar, AstraZeneca, Myriad Genetic Laboratories Inc, Merck Sharp & Dohme LLC, AGO Research GmbH, Hoffmann-La Roche, Iqvia Pty Ltd, Tesaro, Pfizer, and others.
• Ovarian Cancer Pipeline Therapies- Active comparator: Niraparib, Chemotherapy + bevacizumab followed by bevacizumab, Niraparib, Olaparib, Chemotherapy, Atezolizumab, Bevacizumab, Single agent chemotherapy, OLAPARIB, Durvalumab, Dexamethasone, DOXIL, Trabectedin, OTL38, and others.
• Ovarian Cancer Market Dynamics: Ovarian Cancer Market Drivers and Barriers
• Ovarian Cancer Market Access and Reimbursement, Unmet Needs, Future Perspectives
Read the Full Research Report of the Ovarian Cancer Market Forecast Report, click here for Ovarian Cancer Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1 Key Insights
2 Report Introduction
3 Ovarian Cancer Market Overview at a Glance
4 Executive Summary of Ovarian Cancer
5 Epidemiology and Market Methodology
6 Disease Background and Overview
7 Diagnosis of Ovarian Cancer
8 Current Treatment Practices of Ovarian Cancer
9 Epidemiology and Patient Population
10 Patient Journey
11 Key Endpoints in Ovarian Cancer Clinical Trials
12 Marketed Therapies
13 Emerging Therapies
14 Conjoint Analysis
15 Ovarian Cancer : 7 Major Market Analysis
16 Market Access and Reimbursement
16.3 Patient Access Programs
17 KOL Views
18 SWOT Analysis
19 Unmet Needs
20 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
Consult with our Business Expert regarding "Ovarian Cancer Market Landscape" @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Trending Market Reports in 2023
Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services
Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market
Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market
Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market
Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market
Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services
Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market
Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Market Size is expected to witness a major change in the study period 2019-2032 here
News-ID: 2986950 • Views: …
More Releases from DelveInsight Business Research
Urticaria Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Ap …
As per DelveInsight's assessment, globally, Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Urticaria Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market.
The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from…
Artificial Intelligence (AI) in Remote Patient Monitoring Market is expected to …
DelveInsight's "Artificial Intelligence (AI) in Remote Patient Monitoring Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Remote Patient Monitoring companies actively working in the market.
According to DelveInsight's analysis, The AI in Remote Patient Monitoring market, valued at USD 1,926.51 million in…
Artificial Intelligence (AI) in Precision Medicine Market is expected to reach U …
DelveInsight's "Artificial Intelligence (AI) in Precision Medicine Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Precision Medicine companies actively working in the market.
According to DelveInsight's analysis, The AI in Precision Medicine market, valued at USD 1,036.91 million in 2024, is expected…
AI in Diagnostics market is expected to reach USD 8,081.97 million by 2032 | Del …
DelveInsight's "Artificial Intelligence (AI) in Diagnostics Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Diagnostics companies actively working in the market.
DelveInsight Analysis: The AI in Diagnostics market, valued at USD 1,623.20 million in 2024, is projected to expand at a compound…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
